23rd Jan 2026 11:23
RTW Biotech Opportunities Ltd - Guernsey-based investor in the life sciences sector - Corxel Pharmaceuticals Ltd, RTW's largest private investment, has completed Series D-1 financing worth USD287 million. Says Corxel is a clinical-stage biopharmaceutical company developing therapies for cardiometabolic conditions, and its lead candidate, CX11, is an oral GLP-1 receptor agonist for obese and overweight patients currently in a phase 2 US trial. Expects the financing proceeds to support the advancement of this trial, as well as a planned global phase 2 trial in type 2 diabetes mellitus and initial preparations for phase 3 studies and other cardiometabolic programmes.
RTW says Corxel represents 6.2% of its net asset value as of December 31, and a quarter of its overall private investment exposure. Says it converted its convertible notes into Series D-1 shares as part of the financing. Its pro-forma holding in Corxel is valued at USD53.9 million.
Current stock price: USD2.21
12-month change: up 67%
By Emma Curzon, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Rtw Biotech